【摘要】 目的研究依达拉奉联合瑞舒伐他汀治疗颅内动脉瘤破裂术后脑血管痉挛的治疗效果。方法随机选取我院2017年3月～2018年3月期间收治的患者共计60例,按照随机数字表法分为研究组(n=30)和参照组(n=30),参照组患者使用依达拉奉治疗,研究组患者使用依达拉奉联合瑞舒伐他汀治疗,对比分析两组患者大脑中动脉血流速度(MCA)、神经功能缺损评分(NIHSS)、不良反应发生情况及治疗效果。结果在动脉血流速度对比中,两组患者治疗前大脑中动脉血流速度差异无统计学意义(P> 0.05),经治疗后,两组治疗前后差异有统计学意义(P <0.05),且研究组明显低于参照组,差异有统计学意义(P <0.05);在神经功能缺损评分对比中,两组患者治疗前神经功能缺损评分对比差异无统计学意义(P> 0.05),经治疗后,两组治疗前后差异有统计学意义(P <0.05),研究组神经功能缺损评分优于参照组,统计学差异有统计学意义(P <0.05);在不良反应发生情况对比中,研究组与参照组在脑梗死发生率、脑血管痉挛发生率及死亡率方面差异均不显著,组间对比差异无统计学意义(P> 0.05);在治疗效果对比中,研究组患者治疗总有效率为83.33%,参照组患者治疗总有效率为53.33%,研究组明显高于参照组,经统计学对比分析差异有意义(P <0.05)。结论依达拉奉联合瑞舒伐他汀对颅内动脉瘤破裂术后脑血管痉挛患者的治疗效果显著,可在临床实践中予以广泛推广和应用。更多还原

【Abstract】 Objective To study the therapeutic effect of edaravone and rosuvastatin in the treatment of cerebral vasospasm after intracranial aneurysm rupture. Methods Sixty patients in our hospital from March 2017 to March 2018 were randomly selected and randomly divided into study group(n=30) and reference group(n=30). The reference group was treated with edaravone and the study group was treated with edaravone combined with rosuvastatin. The MCA, NIHSS, incidence of adverse reactions and treatment effects between the two groups were compared. Results There was no significant difference in the blood flow velocity of the middle cerebral artery in the two groups before treatment(P > 0.05), there was a significant difference between the two groups before and after treatment(P < 0.05), and the study group was significantly lower than the reference group, with statistical significance(P < 0.05). There was no significant difference in the scores of neurological deficits before treatment between the two groups(P > 0.05), there was a significant difference between the two groups after treatment(P < 0.05). The neurological deficit scores in the study group were better than those in the reference group, with statistically significant differences(P < 0.05). There were no significant differences in the incidence of cerebral infarction, incidence of cerebral vasospasm and mortality between the study group and the reference group(P > 0.05). The total effective rate of the study group was 83.33%, which was significantly higher than that of the reference group(53.33%). The difference in comparison analysis was significant(P < 0.05). Conclusion The efficacy of edaravone combined with rosuvastatin in the treatment of cerebral vasospasm after intracranial aneurysm rupture is significant, and it can be widely used and applied in clinical practice.更多还原